Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
Research and development	$ 36,309	$ 42,580	$ 74,104	$ 84,902
In process research and development	15	15	30	35
General and administrative	9,976	11,277	20,108	23,278
Total operating expenses	46,300	53,872	94,242	108,215
Loss from operations	(46,300)	(53,872)	(94,242)	(108,215)
Other income (expense)
Interest income	695	300	1,282	524
Interest expense	(3,429)	(3,481)	(6,929)	(6,948)
Other income, net	6,538	587	8,228	388
Total other income (expense), net	3,804	(2,594)	2,581	(6,036)
Net loss	(42,496)	(56,466)	(91,661)	(114,251)
Other comprehensive income (loss):
Foreign currency translation	1	(138)	24	(146)
Unrealized gain (loss) on marketable securities	(46)	(36)	69	(413)
Other comprehensive income (loss)	(45)	(174)	93	(559)
Comprehensive loss	$ (42,541)	$ (56,640)	$ (91,568)	$ (114,810)
Net loss per share, basic (in dollars per share)	$ (0.45)	$ (0.74)	$ (0.96)	$ (1.50)
Net loss per share, diluted (in dollars per share)	$ (0.45)	$ (0.74)	$ (0.96)	$ (1.50)
Weighted average common shares outstanding, basic (in shares)	95,446,929	76,668,162	95,160,204	76,283,564
Weighted average common shares outstanding, diluted (in shares)	95,446,929	76,668,162	95,160,204	76,283,564